Clinical data from the Phase I/II trial of TG01 in resected pancreatic cancer will be presented at the American Society of Clinical Oncology (ASCO) meeting, announces Targovax.
Pancreas cancer
The overall survival data from the first cohort of patients in the trial was encouraging with 68% of evaluated patients surviving after 2 years. Even though the study cohort is small and there is no control arm included, in comparison with prior published survival rates the results are favourable.
TG01 is an injectable peptide-based onco-immunotherapy that is co-administered with GM-CSF in patients with resected pancreatic cancer undergoing chemotherapy, gemcitabine.
“We are encouraged by two-year overall survival rate patients treated with TG01 in this trial, versus the expected rate from published historical data when treating with gemcitabine alone, the current standard of care,” said Dr Magnus Jäderberg, chief medical officer of Targovax. “Whilst acknowledging the small size of this first patient cohort and the lack of a control arm, we are encouraged by what seems to be a signal of efficacy in this highly malignant and difficult to treat cancer.
“This key milestone for Targovax also triggers a further iteration of plans for the future clinical development of TG01. We have submitted an abstract to the ASCO annual meeting in June when we plan to present the full data.”